Plain-English translation of NCT07045155 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a new medication called pegmolesatide to help treat anemia (low red blood cell counts) in people who depend on dialysis due to kidney disease. The study compares pegmolesatide alone, the current standard treatment alone, and a combination of pegmolesatide with another medication. The goal is to see which approach most effectively raises blood counts in patients who haven't responded well enough to their current treatment.
Many dialysis patients develop anemia as a complication of kidney disease, and some don't respond adequately to current medications. This trial exists to find out whether this new treatment works better, either used alone or combined with other therapies, for patients whose blood counts remain too low.
You likely qualify if…
You likely don't qualify if…
You would visit one of 20 hospitals in China over 24 weeks. You'll start with a screening period (about 4 weeks), then enter a 16-week treatment phase followed by an 8-week extension period. During the study, you'll receive either the new medication alone, your current medication followed by the new medication, or a combination of two medications. You'll have regular blood tests to monitor how well the treatment is working and to check for any side effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China